High-dose melphalan with autologous hematopoietic SCT (HSCT) improves response rates and survival in myeloma. This is despite the fact that unlike other hematologic malignancies treated with high-dose therapy and autotransplantation, autografted myeloma patients continue to relapse several years after transplantation and the procedure is not curative in the majority of patients. However, patients surviving for several years with essentially normal quality of life may be considered to be 'operationally cured.' Also, unlike with other hematologic malignancies relapsing after an autograft, recurrent disease can be treated with novel agents or repeat highdose chemotherapy and autologous or allogeneic HSCTand long-term survival is seen in a number of patients after relapse. Although tandem transplantation is clearly superior to a single autograft, it is unclear if this should be offered to all patients routinely or only to those not attaining CR after one transplant. It is also unclear if novel agents should be used before transplantation or reserved for relapse. Despite their excellent activity, there is no evidence that novel agents such as thalidomide, bortezomib and lenalidomide can replace high-dose chemotherapy and HSCT, and the best strategy is to use all options in all eligible patients at appropriate stages of the disease.
Introduction
The 1980s saw the demonstration of the activity of highdose melphalan in myeloma.
1-3 However, unlike diseases such as acute leukemia, relapse after autotransplantation is almost inevitable in myeloma and the procedure is likely not curative in the majority of patients. Although autotransplantation is not curative in myeloma in the conventional sense in the vast majority of patients, there are significant benefits with the therapy in terms of prolongation of survival with normal quality of life. This is a phenomenon we have termed 'operational cure'. 5, 6 With the availability of effective salvage therapy, 7 survival after post-transplant relapse can also be prolonged (Figure 2 ). Indeed, long-term follow-up studies of high-dose therapy with single 4 or tandem 8 autotransplantation show that one-third of the patients are alive at 10 years.
Patients in their 60s and 70s have received high-dose melphalan with autotransplantation. 9, 10 As disease-specific biologic features are the major determinants of prognosis in myeloma, age also makes a modest contribution to outcome in patients receiving high-dose melphalan ( Figure 3 ).
Is high-dose chemotherapy with autotransplantation beneficial?
High-dose and conventional-dose chemotherapy have been compared prospectively in a number of studies. [11] [12] [13] [14] [15] These studies have been discussed in depth recently. 5 Three of the five studies showed benefit from high-dose therapy with higher response rates, and longer event-free survival (EFS) and overall survival (OS).
The Spanish study 14 showed no benefit from high-dose therapy. The reasons for this may have been that only patients responding to induction therapy were included; eight additional cycles of VBMCP-VBAD chemotherapy were administered to the conventional therapy group after initial induction; 18% of patients in the conventional therapy group underwent transplantation; and 30% of patients in the highdose therapy group received 140 mg/m 2 melphalan with TBI, a regimen shown to be inferior to 200 mg/m 2 melphalan. [16] [17] [18] The French GMA study 15 showed a trend toward better EFS and better quality of life as measured by time without symptoms, treatment and treatment toxicity (TwiSTT) with high-dose therapy. However, OS was not better in the transplant group. The reasons for lack of difference in OS may have been similar to those discussed above for the Spanish study.
The treatment approaches in these five studies was very heterogeneous, making comparison between studies difficult. However, it is noteworthy that in these studies, between 10 and 26% of patients randomized to high-dose therapy did not undergo HSCT, and between 9 and 23% of patients randomized to conventional-dose therapy underwent autotransplantation; either as primary therapy or as salvage therapy. As the studies were analyzed on an intentto-treat basis, the net effect of crossover between groups is to reduce the magnitude of the difference made by highdose therapy.
When should transplantation be performed?
Autotransplantation can be performed as consolidation therapy after initial induction ('early') or for disease that has relapsed following an initial response ('late'). Two randomized studies have addressed the early vs late transplant question. 19, 20 In the French study, 19 185 patients were randomized to early (n ¼ 91) or late (n ¼ 94) high-dose therapy after undergoing stem cell apheresis during recovery from one to two courses of CHOP. The late transplant group received 1-20 cycles of VMCP (median 8), and 73 (90% of those eligible) received high-dose therapy for primary refractory or relapsed disease. Eighty-nine percent of the early transplant group underwent transplantation as planned. The conditioning regimen comprised BCNU, etoposide, 140 mg/m 2 melphalan and TBI. The 4-year OS was 66% in the early group and 61% in the late group. The median OS exceeded 5 years in both groups. The median EFS was significantly longer (39 months) in the early group compared to 13 months in the late group. The average TwiSTT duration was better for early (28 months) than for late (22 months) transplantation.
In the US Intergroup study, 20 patients received three to four cycles of VAD chemotherapy followed by randomization to transplant (n ¼ 261) or no transplant (n ¼ 255), and then high-dose CY and stem cell collection. As stem cells were collected in all randomized patients and there was a provision for salvage autotransplantation at relapse in the nontransplant group (although this was not mandatory), this was really an early vs late transplant study. The conditioning regimen comprised 140 mg/m 2 melphalan and 12 Gy TBI, and 213 (82%) of the patients randomized to autotransplantation underwent the procedure. The nontransplant group patients received VMCP maintenance therapy until progression. Outcomes from the time of randomization were comparable for the transplant and nontransplant groups: 7-year EFS and OS were 17 and 38% in autograft group, and 14 and 38% in the Years after relapse following autograft nontransplant group. Follow-up was available on 157 patients relapsing on the nontransplant arm; 87 (55%) of whom underwent autotransplantation as salvage therapy. The median OS of these patients from the time of relapse was 30 months, compared with 23 months for the 70 relapsing patients who did not receive a salvage autograft (P ¼ 0.13). No quality-of-life studies were done; an important point to consider because patients in the nontransplant arm remained on therapy for longer periods of time. Use of a TBI-based conditioning regimen was an obvious factor contributing to poor outcome of the autografted group in this study. Other concerns are high patient attrition rates through stages of therapy, a significant proportion of patients lost to follow-up and lack of information on the conditioning regimen used for salvage transplantation.
The disadvantages of waiting until relapse include a longer time on chemotherapy, possible organ deterioration (for example, renal failure) should the disease relapse explosively and a higher risk of eventual myelodysplastic syndrome if treated with low-dose alkylating agent therapy. The advantage of waiting is avoidance or postponement of transplantation in a small proportion of patients who may survive for several years without disease progression. In any case, myeloma patients at all phases of the disease can potentially benefit from high-dose therapy; albeit to a variable extent.
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What is the role of tandem transplantation?
The University of Arkansas Total Therapy 1 program comprised remission induction with 2-3 cycles of VAD, high-dose CY with GM-CSF for stem cell mobilization, EDAP (etoposide, dexamethasone, cytarabine, cisplatin) intensification, followed by tandem autotransplantation (two elective procedures a few months apart) and maintenance therapy with INF-a2b. 22 The conditioning regimen was 200 mg/m 2 melphalan for the first transplant. Patients achieving PR received the same regimen for the second transplant, whereas those not attaining PR received melphalan-TBI or melphalan-cyclophosphamide. Of 231 patients enrolled, 13% had only one transplant and 71% completed both. The overall CR and PR rates were 41 and 42% for the entire group of patients, and 51 and 44% for the 165 patients completing two transplants. Long-term follow-up of the study 8 showed median OS and EFS of 68 and 31 months, and 15-year actuarial OS and EFS probabilities of 17 and 7%, respectively. Despite limitations such as patient selection, these are extraordinary results.
The question of single vs double transplantation is a contentious one, and has been explored in two published studies 23, 24 and two ongoing studies from which preliminary data are available. 25, 26 These studies have been discussed in depth recently. 5 In the IFM 96 study, 23 patients who did not have at least a very good partial response after the first transplant had a significant benefit from the second; with 7-year OS rates being 11% in the single-transplant group and 43% in the double-transplant group (Po0.001). Patients who had at least a very good partial response did not appear to benefit significantly from the second autograft. However, even in this subgroup, the OS curves look as if they are starting separately at the 6-year mark in favor of the doubletransplant group.
In the Bologna 96 study, 24 patients who did not attain CR or near-CR after the first transplant had longer EFS and OS if they were in the double-transplant group. Interestingly, this benefit was seen even in patients who did not attain CR or near-CR after having received the second transplant. Patients who were in CR or near-CR after the first transplant did not appear to benefit significantly from a second transplant.
In the MAG95 study, 25 OS was superior (P ¼ 0.04) after tandem transplantation compared with single in the subgroup of patients receiving unmanipulated stem cells.
In the Dutch prospective HOVON 24 study, 27,28 all patients received three to four cycles of VAD induction chemotherapy followed by randomization to an autograft with CY-TBI or no transplant. All patients received highdose CY and underwent stem cell collection after randomization. Subsequently, both groups received 140 mg/m 2 melphalan in two divided doses 2 months apart without stem cell support. This was followed by an autograft in the high-dose therapy group. This design is more akin to a single vs tandem transplantation study. Although there was no difference in overall response rates, EFS or OS between the arms in the preliminary report, 27 longer term followup 28 showed higher CR rates and EFS with doubleintensive therapy. OS was comparable, possibly because a high proportion of patients from the single-intensive arm underwent autotransplantation at first relapse.
It is not known if tandem transplantation is superior to one transplant followed by a second transplant as salvage therapy of relapsed disease. A second high-dose therapy procedure is thought to be an effective salvage treatment for relapse after earlier autotransplantation in selected patients. 5, 29, 30 A reasonable approach may be to consider tandem autotransplantation in patients who are not in CR or near-CR after the first transplant. In those who are in CR or near-CR, the second transplant could be a salvage procedure in the future rather than an elective tandem procedure. However, until there are longer-term data from the IFM 96 and Bologna 96 studies as well as mature data from the other ongoing studies, there is no evidence to support a dogmatic stand that a planned second autograft should not be performed in patients who are in CR or near-CR after the first transplant.
Is response to induction therapy important?
Unlike most other hematologic malignancies, most myeloma patients are autografted before they have attained CR, and most patients attaining CR do so as a result of the transplant. The prognosis of patients with primary refractory disease is poor if they are treated with conventional-intensity therapy. We have shown that patients with primary refractory disease can benefit from autotransplantation to the same extent as those with responsive disease, 31 because outcome is dependent upon the final response after the transplant independent of response to induction chemotherapy. 5 However, whether patients not responding to induction chemotherapy should proceed immediately to stem cell collection and autotransplantation or receive salvage therapy to attain a response is unknown. We believe that a patient who is refractory to simple induction therapy such as pulse dexamethasone could benefit from the addition of a drug such as thalidomide, lenalidomide or bortezomib to derive a response before stem cell collection and transplantation, or from proceeding straight to stem cell collection and transplantation. The path chosen should be dictated by logistics. In contrast, a patient initially treated with more powerful induction chemotherapy such as thalidomidedexamethasone should probably proceed immediately to stem cell collection and transplantation if the disease is unresponsive.
A pilot study showed that patients undergoing stem cell collection at the time of diagnosis after a single 5-day pulse of high-dose methylprednisolone and then receiving highdose melphalan and autotransplantation as primary therapy did as well as those receiving several cycles of induction chemotherapy and then undergoing transplantation with the disease under some control. 32 This observation calls into some question the contribution of induction chemotherapy to disease control if a transplant is planned. However, induction therapy is clearly essential to stabilize organ function and to improve performance status as the logistics of stem cell collection and transplantation are being organized.
What is the role of new agents before autotransplantation?
Large phase II investigations of high-dose therapy have used standard cytotoxic combinations such as pulse dexamethasone alone, VAD or VAMP/C-VAMP 6 for induction. It has been shown now that VAD and dexamethasone are equivalent in patients subsequently undergoing autotransplantation. 33 On the basis of a randomized study that showed significantly higher response rates with the combination of thalidomide and dexamethasone compared with dexamethasone alone, the combination has become standard first-line therapy despite significantly greater toxicity and expense. 34 However, the equivalent survival in the two arms suggest that subsequent autotransplantation overcame any early differences. 35 Post-autograft EFS and OS of patients induced with VAD, dexamethasone and thalidomidedexamethasone has now been shown to be identical in a retrospective study. 36 There may also be logistic problems with using thalidomide. In some patients, thalidomide may have a temporary inhibitory effect on stem cell mobilization with G-CSF. The drug, if used, should be stopped at least 4 weeks before mobilization. Deep vein thrombosis is a major problem in patients receiving thalidomide or lenalidomide with dexamethasone for induction. Prophylactic or therapeutic anticoagulation, in addition to the inconvenience, expense, and risk of bleeding, makes subsequent management such as insertion of a large-bore apheresis catheter difficult.
Data exist showing excellent activity of lenalidomide and bortezomib in newly diagnosed myeloma without any detrimental effect on stem cell collection. However, in patients who are to undergo autotransplantation, any beneficial effect of using one the three new agents for induction is not apparent and cannot be recommended as a routine. Indeed, data from the Arkansas Total Therapy 2 study 37 show that in patients getting thalidomide from the beginning of therapy and continuing it all the way through have better response rates and EFS than patients not receiving thalidomide, but their post-relapse survival is much poorer leading to OS rates that are comparable. These results should lend a strong note of caution against widespread inclusion of novel agents in pre-transplant treatment regimens outside of clinical trials.
Unless a patient is on clinical trial involving one of the new agents, our standard approach is to use three 4-or 5-week cycles of pulse dexamethasone for induction. Thalidomide or bortezomib are added if there is inadequate response to the first or second cycle. After a total of three cycles of therapy, stem cells are mobilized with CDEP (CY, dexamethasone, etoposide, cisplatin). Patients with highrisk disease (high LDH, high plasma-cell labeling index, plasma cell leukemia) are treated with aggressive combination chemotherapy from the beginning.
Should maintenance therapy be used post-transplant?
As autotransplantation is not curative in myeloma, the use of post-transplant maintenance therapy to prolong the duration of disease control is logical. An early randomized study showed significantly longer EFS with interferon-a, OS was comparable. 38 On the basis of this study, the use of interferon became widespread. However, the drug is myelosuppressive and causes significant constitutional symptoms leading to poor quality of life. With the availability of new drugs such as thalidomide 39 and a recent study showing no benefit, 20 interferon has fallen out of favor. The use of corticosteroids as maintenance therapy is reasonable in patients whose disease is not known to be steroid-refractory. A recent randomized study showed better EFS and OS in patients receiving thalidomide maintenance after autotransplantation. 40 However, in patients with disease known to be responsive to steroids pre-transplant, it is unclear if steroids or thalidomide should be used. Neither thalidomide nor corticosteroids have a role in patients with disease not responding well to thalidomide-dexamethasone induction. In such patients and in those who cannot tolerate steroids or thalidomide, bortezomib at the dose of 1.3 mg/m 2 once every 4 weeks is being evaluated.
Is the extent of the final response relevant?
Some high-dose therapy studies show better outcome for patients achieving CR, whereas others do not. The most important difficulty with evaluating the contribution of CR to outcome in a group of patients is the differential impact of disease biology on attainment of CR and response duration. For example, some powerful adverse risk factors such as elevated LDH and IgA isotype are associated with a higher likelihood of attaining CR but lower response duration. Should the goal of therapy in every myeloma patient therefore be to achieve CR? As CR, despite the limitations of its definition and its heterogeneity in myeloma, represents maximal cytoreduction, it is logical to pursue CR as a goal in practice.
What are the factors affecting outcome?
Several adverse prognostic factors have been identified: high b2-microglobulin, low albumin, del13/13q-, high LDH, high C-reactive protein, plasmablastic morphology, t(4;14), thrombocytopenia, high plasma-cell labeling index, del(17p), hypodiploidy, 1p/q abnormalities, advanced age and renal dysfunction. The most widely available of these are albumin and b2-microglobulin, which have been combined to generate an 'International Staging System.' The median survival of high-dose chemotherapy-treated patients with ISS stages I, II and III, on an intent-to-treat basis, is 90, 61 and 40 months, respectively. 41 These survival durations have been measured from the start of initial therapy, and therefore are approximately 6 months longer than those measured from the time of transplantation.
The poor post-transplant outcome of some subgroups of patients-such as those with del(13) or 13q-detected on metaphase karyotyping 42, 43 -is sometimes construed as a lack of benefit of high-dose therapy. This is incorrect. Such an interpretation requires data showing no difference in outcome between conventional-and high-dose therapy in these subgroups-and not simply data showing poor outcome after high-dose therapy. It is possible that these subgroups may have an even poorer outcome after conventional-dose therapy. Unfortunately, none of the prospective studies have compared the impact of cytogenetics and other prognostic factors in the context of chemotherapy intensity. A more reasonable interpretation of the available data is that autotransplantation does not eliminate the difference between good-and poor-risk patients, and that further improvement in the outcome of such patients requires a change in strategy. An excellent case can be made for enrolling such patients on clinical trials exploring novel treatment approaches as an alternative to standard autotransplantation. However, in the absence of access to appropriate studies, proceeding with high-dose therapy is appropriate until alternatives proven to be superior are found.
Extreme regression analysis is an interesting method is to identify small subgroups of patients with very good or very poor prognosis. 44 An example of such an analysis on the Royal Marsden Hospital group of patients is shown in Figure 4 . Gene expression profiling may eventually turn out to be the most important prognostic predictor in myeloma. However, data available currently are limited.
Can new agents replace autotransplantation?
The discovery of the dramatic activity of thalidomide in relapsed and/or refractory myeloma, 39 and 20% 7-year survival in patients with near-terminal disease 45 transformed the treatment of recurrent myeloma. This was followed by the development of two other active agents; bortezomib 46 and lenalidomide. 47 These agents are also very active in untreated disease leading to speculation that these newer agents may replace high-dose chemotherapy. Only a prospective, randomized study can answer this question. The limited available evidence suggests that median response durations in patients treated with frontline thalidomide-dexamethasone and bortezomib-dexamethasone are of the order of 18-24 months-and are thus shorter than the response durations seen after autotransplantation. It is therefore premature to consider abandonment of the use of high-dose therapy.
Just as thalidomide has improved the survival of autograft recipients relapsing in the thalidomide era compared to those relapsing before its availability, 8 it is logical to expect that the sequential use of autografts and novel agents would be superior to the use of novel agents without high-dose therapy. For an individual patient, it is important to plan therapy in a manner that uses all active agents-chemotherapeutic or otherwise-appropriately and sequentially as none of the treatments need be mutually exclusive.
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